Casimersen
Duchenne Muscular Dystrophy
Kevin Flanigannucleic_acidPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 81/ 100
Competitive context
55 Active assets in the Duchenne Muscular Dystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Viltolarsen NS Pharma, Inc. | Phase 4 | BBB |
Delandistrogene Moxeparvovec Sarepta Therapeutics, Inc. | Phase 3 | BB |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | BB |
Golodirsen Rare Disease Research, LLC | Phase 4 | BB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Anne M. Connolly | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →